TScan Therapeutics, Inc. Common Stock (TCRX) Stock Price

TCRXStock

$0.79−57.26%52W

Market Cap$53.80M

P/E—

PEG Ratio—

Div yield—

Beta1.14

TCRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-32.88%

Price vs S&P 500 (4W)0.22%

VGM Score45.01

Book Value / Share (Quarterly)$1.61

P/TBV (Annual)2.46x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.64%

Cash Flow / Share (Quarterly)$-2.08

Price vs S&P 500 (YTD)-32.03%

Net Profit Margin (TTM)-1360.61%

EPS (TTM)$-0.96

10-Day Avg Trading Volume0.31M

EPS Excl Extra (TTM)$-0.96

Revenue Growth (5Y)56.78%

EPS (Annual)$-1.00

ROI (Annual)-83.37%

Net Profit Margin (5Y Avg)-1435.40%

Cash / Share (Quarterly)$2.13

Revenue Growth QoQ (YoY)-54.77%

ROA (Last FY)-56.72%

Revenue Growth TTM (YoY)106.65%

EBITD / Share (TTM)$-0.97

ROE (5Y Avg)-62.86%

Operating Margin (TTM)-1408.73%

Cash Flow / Share (Annual)$-2.46

P/B Ratio0.52x

P/B Ratio (Quarterly)0.58x

Net Income / Employee (Annual)$-913,800

EV / Revenue (TTM)-4.92x

ROA (TTM)-50.14%

EPS Incl Extra (Annual)$-1.00

Current Ratio (Annual)8.41x

Quick Ratio (Quarterly)6.41x

3-Month Avg Trading Volume0.69M

52-Week Price Return-57.26%

Revenue / Employee (TTM)$64,300

Tangible BV / Share (Quarterly)$3.53

P/S Ratio (Annual)4.89x

Asset Turnover (Annual)0.05x

52-Week High$2.57

Operating Margin (5Y Avg)-1511.52%

EPS Excl Extra (Annual)$-1.00

CapEx CAGR (5Y)0.78%

26-Week Price Return-21.64%

Quick Ratio (Annual)8.15x

13-Week Price Return-21.64%

Total Debt / Equity (Annual)0.26x

Current Ratio (Quarterly)6.65x

Enterprise Value$-44.95M

Revenue / Share Growth (5Y)11.49%

Asset Turnover (TTM)0.04x

Revenue / Employee (Annual)$72,700

Pretax Margin (Annual)-1256.81%

Cash / Share (Annual)$2.68

3-Month Return Std Dev84.67%

Net Income / Employee (TTM)$-875,400

ROE (Last FY)-105.40%

EPS Basic Excl Extra (Annual)$-1.00

Total Debt / Equity (Quarterly)0.34x

EPS Incl Extra (TTM)$-0.96

ROI (TTM)-74.14%

P/S Ratio (TTM)5.52x

Pretax Margin (5Y Avg)-1435.40%

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$4.10

Price vs S&P 500 (52W)-75.57%

Year-to-Date Return-20.07%

5-Day Price Return-3.08%

EPS Normalized (Annual)$-1.00

ROA (5Y Avg)-36.59%

Net Profit Margin (Annual)-1256.81%

Month-to-Date Return7.58%

Cash Flow / Share (TTM)$-1.74

EBITD / Share (Annual)$-1.02

Operating Margin (Annual)-1315.38%

LT Debt / Equity (Annual)0.26x

ROI (5Y Avg)-52.22%

LT Debt / Equity (Quarterly)0.34x

EPS Basic Excl Extra (TTM)$-0.96

P/TBV (Quarterly)1.45x

P/B Ratio (Annual)0.46x

Pretax Margin (TTM)-1360.61%

Book Value / Share (Annual)$2.16

Price vs S&P 500 (13W)-24.43%

Beta1.14x

Revenue / Share (TTM)$0.07

ROE (TTM)-91.94%

52-Week Low$0.72

gGradeB

mGradeD

vgmGradeC

TCRX Earnings Surprise History

Q2 25-0.28est. -0.32

Q3 25-0.28est. -0.33

Q4 25-0.18est. -0.28

Q1 26-0.22est. -0.17

Q2 26-0.23est. -0.20

TCRX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
TCRXTScan Therapeutics, Inc. Common Stock	—	B	D	$0.79
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About TScan Therapeutics, Inc. Common Stock

TScan Therapeutics is a clinical-stage biotech company developing T cell receptor (TCR)-engineered T cell therapies to treat cancer. Its pipeline includes TSC-100 and TSC-101, liquid tumor candidates designed to eliminate residual leukemia and prevent relapse following hematopoietic stem cell transplantation, plus multiplexed TCR-T candidates for solid tumors.